<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Patients with transformed <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo>(<z:mp ids='MP_0005481'>CML</z:mp>) and advanced <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>(<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) have poor prognosis </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study is to evaluate the feasibility of second <z:hpo ids='HP_0011010'>chronic</z:hpo> phase induction in accelerated phase(<z:mp ids='MP_0005481'>CML</z:mp>-AP) or blastic crisis of <z:mp ids='MP_0005481'>CML</z:mp>(<z:mp ids='MP_0005481'>CML</z:mp>-BC) and remission induction in advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> by combining <z:chebi fb="0" ids="50276">topoisomerase I inhibitor</z:chebi> (topotecan) with <z:chebi fb="0" ids="50750">topoisomerase II inhibitor</z:chebi>(<z:chebi fb="0" ids="50729">mitoxantrone</z:chebi>) </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Twenty-four evaluable patients were entered on this study with a median age of 34 years </plain></SENT>
<SENT sid="3" pm="."><plain>Eighteen patients with transformed <z:mp ids='MP_0005481'>CML</z:mp>(7 <z:mp ids='MP_0005481'>CML</z:mp>-AP, 11 <z:mp ids='MP_0005481'>CML</z:mp>-BC) and 6 patients with advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were treated </plain></SENT>
<SENT sid="4" pm="."><plain>Topotecan was administered as 1.5 mg/m2/day by continuous infusion over 24 hours daily for 5 days every 4 to 8 weeks until remission </plain></SENT>
<SENT sid="5" pm="."><plain>To enhance the tumoricidal effects, <z:chebi fb="0" ids="50729">mitoxantrone</z:chebi>(12 mg/m2/day, Days 1-3) was added </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Eight patients(33%) achieved a complete remission(CR) </plain></SENT>
<SENT sid="7" pm="."><plain>Four of 7 patients with <z:mp ids='MP_0005481'>CML</z:mp>-AP(57%), 2 of 4 patients with <z:mp ids='MP_0005481'>CML</z:mp>-lymphoid blastic crisis (-LBC)(50%) and 2 of 6 patients with advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>(33%) had CR lasting more than 45 days(45 to 400 days) </plain></SENT>
<SENT sid="8" pm="."><plain>There was no CR in the patients with <z:mp ids='MP_0005481'>CML</z:mp>-myeloid blastic crisis(-MBC) </plain></SENT>
<SENT sid="9" pm="."><plain>The dose level of 1.5 mg/m2/day(7.5 mg/m2/course) of topotecan was well tolerated in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="10" pm="."><plain>Mucositis occurred in 69% of patients (severe in 5%) and <z:hpo ids='HP_0002014'>diarrhea</z:hpo> in 67%(severe in 8%) </plain></SENT>
<SENT sid="11" pm="."><plain>In addition, there were no new or unexpected toxicities in the patients who were treated at this dose(7.5 mg/m2/course) </plain></SENT>
<SENT sid="12" pm="."><plain>In patients who recovered their neutrophil count, the absolute neutrophil count(ANC) remained below 500/microL for a period of 13 to 58 days(median 21 days) and the time to ANC recovery was associated with pretreatment severity of bone marrow <z:mp ids='MP_0003045'>fibrosis</z:mp>(mainly <z:mp ids='MP_0005481'>CML</z:mp> patients) </plain></SENT>
<SENT sid="13" pm="."><plain>Likewise, in the patients who recovered unsupported platelets, the platelets remained below 20,000/microL for a period of 0 to 37 days (median 19 days) </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSION: The combination of topotecan-<z:chebi fb="0" ids="50729">mitoxantrone</z:chebi> has shown modest activity in <z:mp ids='MP_0005481'>CML</z:mp>-AP, <z:mp ids='MP_0005481'>CML</z:mp>-LBC and advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with acceptable toxicities </plain></SENT>
</text></document>